3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
376
Neoplasm Metastasis
21
Neoplasms
11
Advanced Breast Cancer
10
Carcinoma, Intraductal, Noninfiltrating
8
Triple Negative Breast Neoplasms
7
Osteoporosis
7
Carcinoma, Ductal, Breast
7
Breast Neoplasms, Male
7
Breast Diseases
7
Breast Carcinoma In Situ
6
Carcinoma, Lobular
5
Prostatic Neoplasms
4
Hereditary Sensory and Autonomic Neuropathies
4
Breast Cancer Metastatic
4
Arthralgia
4
Recurrence
3
Ovarian Neoplasms
3
Neoplasms, Hormone-Dependent
3
Squamous Cell Carcinoma of Head and Neck
2
Pain
2
Obesity
2
Neoplasms by Site
2
Multiple Endocrine Neoplasia Type 1
2
Infertility
2
Head and Neck Neoplasms
2
HR+/HER2- Breast Cancer
2
HR Positive HER2 Negative Advanced Breast Cancer
2
Estrogen Receptor-positive Breast Cancer
2
Endometrial Neoplasms
2
Interventions
pembrolizumab
3
spartalizumab
2
sargramostim
2
trametinib
1
tislelizumab
1
nazartinib
1
fludarabine phosphate
1
enzalutamide
1
canakinumab
1
bemarituzumab
1
Specimen Handling
1
Midazolam
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Interleukin-13
1
IFL protocol
1
Fulvestrant
1
Fluorodeoxyglucose F18
1
Cyclophosphamide
1
Cetuximab
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
Letrozole
×
Breast
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled